Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Fall Home Improvement
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by VALNEVA
< Previous
1
2
Next >
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
March 26, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F
March 25, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C.
March 21, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
March 20, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed
March 18, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
March 04, 2024
From
VALNEVA
Via
GlobeNewswire
U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ®
February 29, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance
February 15, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva Announces Sale of Priority Review Voucher for $103 Million
February 05, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya Vaccine
January 10, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference and Oddo BHF Forum
January 04, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva Provides Updated 2023 Financial Guidance
December 29, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Shareholders Approve EGM Resolutions Including the Transition to a Board of Directors
December 20, 2023
From
VALNEVA
Via
GlobeNewswire
Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15
December 04, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Reports Positive 24-Month Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®
December 04, 2023
From
VALNEVA
Via
GlobeNewswire
EMA Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment
November 27, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Announces the Availability of Documentation for its Extraordinary General Meeting including Planned Changes to its Future Board of Directors
November 15, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Reports Positive Pivotal Phase 3 Immunogenicity Data in Adolescents for its Single-Shot Chikungunya Vaccine Candidate
November 13, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Announces U.S. FDA Approval of World’s First Chikungunya Vaccine, IXCHIQ®
November 10, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Reports Nine-Month 2023 Financial Results and Provides Corporate Updates
November 09, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference
November 07, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Submits Chikungunya Vaccine Marketing Application to EMA and Announces CHMP Accelerated Assessment
October 25, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva to Present on Chikungunya at Several Leading Scientific Conferences
October 11, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32 Million
September 25, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Reports Half Year 2023 Financial Results and Provides Corporate Updates
September 21, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate
September 07, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva to Participate in Investor Conferences in the United States and Europe in September 2023
August 31, 2023
From
VALNEVA
Via
GlobeNewswire
Health Canada Accepts Valneva’s Chikungunya Vaccine License Application for Review
August 29, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Reports Positive Initial Phase 3 Safety Data in Adolescents for its Single-Shot Chikungunya Vaccine Candidate
August 28, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Announces Extension of Existing Loan Agreement
August 17, 2023
From
VALNEVA
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.